Organised by Virology Education in close collaboration with local societies, COLDA 2020 aims at empowering African healthcare professionals (HCPs) to diagnose, prevent, treat and achieve a cure for liver diseases for the benefit of patients in Africa. This being the 3rd COLDA, we continue our goal to create a platform that provides a unique opportunity for clinicians, researchers, policymakers, industry representatives, and other healthcare professionals in the African region. Together with support from an international community of experts, they will exchange knowledge on the latest clinical developments and updates on ongoing and new trials related to liver disease.
ICE-HBV is organizing a post-conference interactive workshop on HBV biomarkers in conjunction with the International HBV Meeting. The event is aimed at scientists, clinicians, pharmaceutical and diagnostic industry representatives. The workshop, chaired by Anna Kramvis and Peter Revill, is put together by the ICE-HBV serum biomarkers working group. Both classic and future biomarkers will be discussed. The workshop will lead to a consensus statement on promising serum biomarkers.
Given the evolution of the COVDI-19 epidemic, ANRS has decided to post-pone the workshop. We will keep you informed of the new date once decided.
Hot topics on HBV & HDV Clinical trials, immune exhaustion & immune clearance, cccDNAbiology and targeting, viral integration, viral biomarkers, experimental study models.
This workshop is endorsed by ICE-HBV.
ICE-HBV & EASL will present their joint HBV Cure Think Tank once again in 2020.
EASL and ICE-HBV invite you to a Research Think Tank on April 15 (8 to11 am) in London to discuss the basic and clinical research gaps that need to be overcome to achieve an HBV cure from the scientific and patient perspectives, as well as explore the latest advances and new insights in translational research towards HBV cure. The Think Tank is open to delegates of the International Liver Congress.
A series of short lectures will be followed by in-depth panel discussions on the following topics:
• Novel approaches to accelerate cure in clinical trials
• Are novel biomarkers advancing HBV cure?
• The patient perspective on HBV cure
• Occult infection vs functional cure
• Which patient populations should be included in clinical trials?
• Manipulating the immune system to achieve an HBV cure
• Standardised approaches to detecting the HBV cccDNA reservoir
• Advances in studies of the liver microenvironment through the use of fine needle aspirants
Find out more here.
ICE-HBV and its members will have a strong presence at HepDART 2019, with many important presentations on HBV Cure such as:
Clinical update on drugs for HBV cure*
Harry Janssen, University of Toronto, Canada
What would an HBV cure look? Endpoints and clinical trial design towards a cure*
Anna Lok, University of Michigan, USA
Join them in Hawai by registering here.
ICE-HBV & partners are organizing a session at the Global Fund’s replenishment conference in Lyon. Please contact email@example.com to register (free).
The goal of this session is to underscore the potential public health impact of expanding viral hepatitis elimination programming, including through strategic integration with existing efforts to improve HIV care and prevention outcomes. The full programme is available here.
ICE-HBV is organizing an HBV Cure 101 session at COLDA to enhance awareness about HBV Cure research in Africa. Anna Kramvis will represent ICE-HBV and share an update about the latest sience before discussing cure prospects with Manal El-Sayed (Clinician) and Kenneth Kabagambe (Community).
The 6th edition of the International HBV Cure Workshop 2019, which will take place on 6 November 2019 in Toronto, Canada. Since 2014, the HBV Cure Workshop is a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. This meeting will bring together the world’s leading basic, translational and clinical experts to share and discuss the latest research outcomes and challenges.
Details can be found here.